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Abstract
Background: Serum homocysteine, when studied singly, has been reported to be positively associated both with the
endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine [ADMA, via inhibition of dimethylarginine
dimethylaminohydrolase (DDAH) activity] and with symmetric dimethylarginine (SDMA). We investigated combined
associations between transsulfuration pathway thiols, including homocysteine, and serum ADMA and SDMA concentrations
at population level.
Methods: Data on clinical and demographic characteristics, medication exposure, C-reactive protein, serum ADMA and
SDMA (LC-MS/MS), and thiols (homocysteine, cysteine, taurine, glutamylcysteine, total glutathione, and cysteinylglycine;
capillary electrophoresis) were collected from a sample of the Hunter Community Study on human ageing [n = 498, median
age (IQR) = 64 (60–70) years].
Results: Regression analysis showed that: a) age (P= 0.001), gender (P= 0.03), lower estimated glomerular filtration rate
(eGFR, P= 0.08), body mass index (P= 0.008), treatment with beta-blockers (P= 0.03), homocysteine (P= 0.02), and
glutamylcysteine (P= 0.003) were independently associated with higher ADMA concentrations; and b) age (P= 0.001),
absence of diabetes (P= 0.001), lower body mass index (P= 0.01), lower eGFR (P,0.001), cysteine (P= 0.007), and
glutamylcysteine (P,0.001) were independently associated with higher SDMA concentrations. No significant associations
were observed between methylated arginines and either glutathione or taurine concentrations.
Conclusions: After adjusting for clinical, demographic, biochemical, and pharmacological confounders the combined
assessment of transsulfuration pathway thiols shows that glutamylcysteine has the strongest and positive independent
associations with ADMA and SDMA. Whether this reflects a direct effect of glutamylcysteine on DDAH activity (for ADMA)
and/or cationic amino acid transport requires further investigations.
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Introduction
The methylated forms of the amino acid L-arginine, asymmetric
(ADMA) and symmetric (SDMA) dimethylarginine, are generated
from the proteolysis of proteins containing methylated arginine
residues [1,2]. Both ADMA and, to a lesser extent, SDMA play an
important role in cardiovascular homeostasis. ADMA is a potent
endogenous inhibitor of endothelium nitric oxide synthase [1,2].
Experimental and human studies have convincingly demonstrated
that ADMA facilitates endothelial dysfunction, vascular damage,
and the onset and progression of atherosclerosis and thrombosis
[3]. Recent reports also suggest a potential, albeit indirect, role of
SDMA in inhibiting nitric oxide synthesis and in favouring
inflammation [4,5]. Clinical studies conducted over the last 20
years have provided solid evidence that higher plasma ADMA
and, more recently, SDMA concentrations independently predict
adverse cardiovascular outcomes in several patient groups with
different cardiovascular risk at baseline [6–11].
Cardiovascular disease biomarkers for clinical use should have
several characteristics, i.e. easily measurable in the population,
predictable relationship with cardiovascular risk, and modification
by means of pharmacological and/or non-pharmacological
interventions [12]. Currently, ADMA and SDMA possess the
first two characteristics. Whilst future clinical studies are likely to
address the issue of ADMA and SDMA modulation in relation to
risk modification an important issue remains the identification of
biological processes and pathways influencing methylated arginine
synthesis and metabolism in humans.
The highly reactive sulphur-containing amino acid homocyste-
ine has long been shown to exert negative effects on endothelial
function by inhibiting nitric oxide synthesis [13]. Similarly to
methylated arginines, several clinical studies have shown that
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higher homocysteine concentrations independently predict ad-
verse cardiovascular outcomes and improve risk reclassification
[13–15]. Notably, a number of human studies have shown positive
associations between homocysteine, ADMA, and SDMA concen-
trations [7,16–19]. The synthesis of ADMA and SDMA is
catalyzed by a family of enzymes called protein-arginine-N-
methyltransferases (PRMT). PRMT utilize S-adenosylmethionine,
an intermediate in the methionine-homocysteine pathway, as a
methyl donor [1]. After donating its methyl group, S-adenosyl-
methionine is transformed into S-adenosylhomocysteine, and then
into homocysteine (Figure 1) [20]. In vitro studies have also
demonstrated that homocysteine inhibits the activity of dimethy-
larginine dimethylaminohydrolase (DDAH), the enzyme respon-
sible for ADMA metabolism [21,22]. These findings suggest a
biological and pathophysiological interplay between homocyste-
ine, methylated arginines, and cardiovascular disease [23].
Homocysteine is the initial step of the transsulfuration pathway
[20]. This biochemical pathway leads to the synthesis of important
cellular and homeostatic thiols such as cysteine, taurine, and the
natural antioxidant glutathione (Figure 1) [24–26]. Little knowl-
edge is currently available on whether there are associations
between transsulfuration pathway thiols and methylated arginines
[27]. Ideally, human studies investigating these associations should
account for a number of clinical, demographic, biochemical, and
pharmacological confounders affecting these pathways
[1,2,13,28,29]. We addressed this issue by examining the
combined associations between transsulfuration pathway thiols
and serum concentrations of ADMA and SDMA at population
level, in an established epidemiological cohort of human ageing.
Methods
Population
The Hunter Community Study (HCS), a collaboration between
the University of Newcastle’s School of Medicine and Public
Health and the Hunter New England Area Health Service, is a
population-based cohort study to assess the impact of clinical,
genetic, biochemical, socioeconomic, and behavioural factors on
human ageing [30]. Participants, a cohort of community-dwelling
subjects aged 55–85 years residing in Newcastle (New South
Wales, Australia), were randomly selected from the electoral roll
and contacted between December 2004 and December 2007.
Invitation letters were sent to 9,784 individuals. Of the 7,575
subjects for whom a response was received, 258 were ineligible
(148 did not speak English, 92 were deceased, and 18 had moved
to an aged-care facility), 3,440 refused, and 3,877 initially agreed
to participate. Of these, a total of 3,253 actually participated
(response rate 44.5%).
After informed, written consent was obtained, subjects were
asked to complete two self-report questionnaires and to return
these when they attended the HCS data collection centre, during
which time a series of clinical and biochemical measures was
obtained. Clinical assessment included a full physical examination
and measurement of blood pressure, heart rate, body mass index,
and waist-to-hip ratio. Routine haematological and biochemical
parameters included full blood count, C-reactive protein (CRP),
fasting lipids, liver and renal function, and fasting blood glucose.
Additional samples were cryopreserved at 286uC and 2196 uC.
Consent to link personal information obtained during the study to
data from Medicare Australia and local health databases was also
sought.
After the clinical assessment a further package of three self-
reporting questionnaires to be returned by reply-paid post was
given to participants to complete at home. The questionnaires
provided details on demographic and socioeconomic character-
istics, nutritional assessment, medical and surgical history,
medication exposure, tobacco use, and alcohol consumption.
Full details of the data collected are described elsewhere [30].
The sample for this investigation (n= 500) was derived from the
initial cohort by simple random sampling. Of the 500 subjects
randomly selected there were complete exposure and outcome
data for 498 subjects. No a priori sample size was determined,
however assuming that at least 10–15 subjects are needed for each
independent variable included in the multivariate analysis the
sample size was more than sufficient to accommodate the number
of co-variables examined in this investigation (see Statistical
analysis paragraph). A comparison of this sample with the entire
cohort showed no significant difference for a range of clinical,
biochemical, socioeconomic, and behavioural factors (data not
shown). The HCS was performed according to the Declaration of
Helsinki. All procedures were approved by the local ethics
committee.
Biochemical Measurements
Blood was collected in EDTA tubes and centrifuged at 4u
and 3000 g for 10 minutes to separate plasma, which was stored
for three years at 280uC before analysis. L-arginine, ADMA,
and SDMA were measured in 0.1 mL serum by hydrophilic-
interaction liquid chromatography and isotope dilution tandem
mass spectrometry [31]. The intra and inter-assay coefficients of
variation (CV) for L-arginine, ADMA, and SDMA were all
,15%. Serum concentrations of the transsulfuration pathway
thiols homocysteine, cysteine, cysteinylglycine, glutamylcysteine,
glutathione, and taurine were measured by laser-induced
fluorescence capillary electrophoresis on 0.05 mL serum for
taurine and 0.2 mL for the other thiols [32,33]. A five-point
calibration curve was used to measure analyte concentrations.
Only for taurine was homocysteic acid used as internal standard
[33]. The minimum detectable concentration for all analytes
was between 200 and 300 pmol/L, with mean recovery
between 98% and 102%. A good reproducibility of intra-assay
(CV ,3.5%) and inter-assay (CV ,6.4%) tests was obtained
[32,33]. High-sensitivity CRP was measured in serum by latex-
enhanced immunoturbidimetry. Estimated glomerular filtration
rate (eGFR) was calculated using the Modification of Diet in
Renal Disease formula [34].
Statistical Analysis
Results are expressed as means 6 SD, medians and inter-
quartile ranges, or frequencies as appropriate. Variables were
tested for normal distribution by using the Kolmogorov-Smirnov
test. Univariate associations between clinical and demographic
variables, thiols, ADMA, and SDMA were assessed by Spearman’s
rank correlation coefficient, two-way ANOVA, and Mann-
Whitney U test. Non-normally distributed variables were log
transformed. Variables showing associations with either ADMA or
SDMA (P,0.2) were entered in linear stepwise regression analysis
to identify factors independently associated with methylated
arginines. Only log-transformed variables were tested in a single
analysis. Multicollinearity was tested by measuring the tolerance
and the variance inflation factor values for each analysis. A total of
31 variables were identified a priori to be potentially associated with
the outcomes of interest: age, gender, body mass index, smoking,
alcohol consumption, history of hypertension, hypercholesterolae-
mia, rheumatoid arthritis, myocardial infarction, stroke, diabetes,
fasting glucose, total cholesterol, HDL and LDL cholesterol,
triglycerides, eGFR, CRP, homocysteine, cysteine, taurine,
glutamylcysteine, glutathione, cysteinylglycine, and use of anti-
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platelet drugs, beta-blockers, angiotensin converting enzyme
inhibitors, statins, diuretics, calcium channel blockers, and
antidiabetic drugs. Considering at least 15 patients per each
confounding variable a minimum sample size of 465 patients was
required for regression analyses [35]. Analyses were performed
using IBM SPSS Statistics 19.0 for Windows (SPSS Inc, Chicago,
IL, USA). A two-sided P,0.05 indicated statistical significance.
The latter was adjusted, P,0.01, in regression analysis to account
for multiple comparisons.
Results
Clinical, demographic, and biochemical characteristics and
medication use of the study population are described in Table 1.
Folic acid and vitamin B12 supplements were used in a relatively
Figure 1. Relationships between the transsulfuration, demethylation, and remethylation pathways. ADMA: asymmetric dimethylargi-
nine, SDMA: symmetric dimethylarginine, SAM: S-adenosylmethionine, SAH: S-adenosylhomocysteine.
doi:10.1371/journal.pone.0054870.g001
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small proportion of participants, 1.8% and 1.4%, respectively.
There were no significant differences in homocysteine and
cysteine concentrations between those with vs. without folic acid
[9.1 (5.9–9.9) vs. 9.1 (7.9–11.0) mmol/L, P=0.32; 178.4629.6
vs. 190.3634.1 mmol/L, P=0.30) and between those with vs.
without vitamin B12 [8.3 (7.7–9.1) vs. 9.1 (7.9–10.9) mmol/L,
P=0.26; 172.0623.6 vs. 190.4634.1 mmol/L, P=0.16).
ADMA
Age, body mass index, lower total and HDL cholesterol, lower
eGFR, CRP, and higher concentrations of all thiols were
associated (P,0.2) with higher ADMA concentrations (Table 2
and Figure S1). Associations were also found with gender (female:
0.5560.07 vs. male: 0.5460.08 mmol/L, P=0.15), regular alcohol
consumption (no: 0.5560.08 vs. yes: 0.5460.07 mmol/L,
P=0.05), hypertension (no: 0.5360.07 vs. yes: 0.5660.08 mmol/
L, P=0.001), myocardial infarction (no: 0.5460.08 vs. yes:
Table 1. Clinical, demographic, biochemical characteristics and medication use.
Variable Study population (n=498)
Age [years, median (IQR)] 64 (60–70)
Females (%) 49.4
Current smoker (%) 6.6
Current alcohol use (%) 69.7
Body mass index [Kg/m2, median (IQR)] 28.0 (25.7–31.2)
Systolic blood pressure (mmHg, mean6SD) 137618
Diastolic blood pressure (mmHg, mean6SD) 80610
Heart rate (b/min, mean6SD) 66611
Hypertension (%) 49.3
Rheumatoid arthritis (%) 5.5
Diabetes (%) 10.8
Hypercholesterolaemia (%) 40.8
Myocardial infarction (%) 5.7
Stroke (%) 2.6
Antiplatelet drugs (%) 2.5
Beta-blockers (%) 21.4
Angiotensin converting enzyme inhibitors (%) 47.4
Calcium-channel blockers (%) 34.9
Statins (%) 13.0
Diuretics (%) 9.7
Antidiabetic drugs (%) 6.5
Folic acid supplements (%) 1.8
Vitamin B12 supplements (%) 1.4
Fasting serum glucose [mmol/L, median (IQR)] 4.8 (4.4–5.4)
Total cholesterol [mmol/L, median (IQR)] 4.9 (4.3–5.8)
HDL-cholesterol [mmol/L, median (IQR)] 1.3 (1.1–1.5)
LDL-cholesterol (mmol/L, mean6SD) 3.160.9
Triglycerides [mmol/L, median (IQR)] 1.1 (0.8–1.6)
eGFRa (mL/min, mean6SD) 79616
C-reactive protein [mg/L, median (IQR)] 2.0 (1.2–3.7)
Homocysteine [mmol/L, median (IQR)] 9.1 (7.9–10.8)
Cysteine (mmol/L, mean6SD) 187.8637.6
Taurine [mmol/L, median (IQR)] 63.3 (52.3–89.7)
Glutamylcysteine (mmol/L, mean6SD) 4.461.2
Glutathione [mmol/L, median (IQR)] 3.9 (3.0–5.3)
Cysteinylglycine [mmol/L, median (IQR)] 29.1 (25.4–33.4)
L-arginine (mmol/L, mean6SD) 55.3618.7
Asymmetric dimethylarginine (mmol/L, mean6SD) 0.5460.08
Symmetric dimethylarginine [mmol/L, median (IQR)] 0.69 (0.61–0.82)
acalculated using the Modification of Diet in Renal Disease formula.
doi:10.1371/journal.pone.0054870.t001
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0.5960.07 mmol/L, P=0.004), stroke (no: 0.5460.08 vs. yes:
0.5860.07 mmol/L, P=0.12), antiplatelet drugs (no: 0.5560.08
vs. yes: 0.5860.08 mmol/L, P=0.16), beta-blockers (no:
0.5460.07 vs. yes: 0.5860.08 mmol/L, P,0.001), angiotensin
converting enzyme inhibitors (no: 0.5460.07 vs. yes:
0.5660.08 mmol/L, P=0.04), statins (no: 0.5460.08 vs. yes:
0.5660.08 mmol/L, P=0.15), and diuretics (no: 0.5460.07 vs.
yes: 0.5960.09 mmol/L, P,0.001).
On regression analysis age, female gender, lower eGFR, body
mass index, treatment with beta-blockers, and the thiols homo-
cysteine and glutamylcysteine were independently associated with
higher serum ADMA concentrations. Glutamylcysteine showed
stronger associations with ADMA concentrations vs. homocysteine
(Table 3).
SDMA
Age, lower body mass index, lower serum glucose, lower total
and LDL cholesterol, lower triglycerides, lower CRP and eGFR,
and higher concentrations of all thiols except taurine were
associated (P,0.2) with higher SDMA concentrations (Table 2
and Figure S2). Associations were also found with regular alcohol
consumption (no: 0.7560.20 vs. yes: 0.7260.17 mmol/L,
P=0.04), diabetes (no: 0.7360.18 vs. yes: 0.6860.17 mmol/L,
P=0.04), myocardial infarction (no: 0.7360.18 vs. yes:
0.7960.20 mmol/L, P=0.05), stroke (no: 0.7260.18 vs. yes:
0.8760.20 mmol/L, P=0.003), antiplatelet drugs (no: 0.7360.18
vs. yes: 0.8460.13 mmol/L, P=0.08), angiotensin converting
enzyme inhibitors (no: 0.7160.16 vs. yes: 0.7660.21 mmol/L,
P=0.007), beta-blockers (no: 0.7260.18 vs. yes: 0.7860.20 mmol/
L, P=0.008), and diuretics (no: 0.7260.17 vs. yes:
0.8260.27 mmol/L, P=0.001).
On regression analysis age, absence of diabetes, lower body
mass index, lower eGFR, and the thiols cysteine and glutamylcys-
teine were independently associated with higher serum SDMA
concentrations (Table 4).
Discussion
Three transsulfuration pathway thiols showed significant,
independent, and positive associations with serum concentrations
of methylated arginines in an established epidemiological cohort of
human ageing. After adjusting for clinical, demographic, bio-
chemical, and pharmacological confounders, homocysteine and
glutamylcysteine were both associated with higher ADMA
concentrations whereas cysteine and glutamylcysteine were both
associated with higher SDMA concentrations. Of note, no
independent associations were observed with the antioxidant
thiols glutathione and taurine.
The transsulfuration pathway regulates important physiological
and homeostatic processes, including detoxification of xenobiotics
or their metabolites, maintenance of intracellular redox balance
and thiol status of proteins, and ensuring cysteine storage within
the c-glutamyl cycle [24–26,36]. Our results confirm previous
reports demonstrating associations between serum homocysteine,
Table 2. Correlations between ADMA and SDMA
concentrations, clinical and demographic factors, and
biochemical variables.
Variable ADMA SDMA
Age r =+0.24, P,0.00001 r = +0.31, P,0.00001
Body mass index r =+0.10, P=0.02 r =20.18,
P= 0.00007
Fasting serum glucose r =20.003, P= 0.95 r =20.16, P=0.001
Total cholesterol r =20.11, P= 0.01 r =20.13, P=0.004
HDL-cholesterol r =20.05, P= 0.24 r = +0.03, P= 0.48
LDL-cholesterol r =20.09, P= 0.06 r =20.06, P=0.17
Triglycerides r =+0.01, P=0.79 r =20.20,
P= 0.00001
eGFR r =20.24, P,0.00001 r =20.47,
P,0.00001
C-reactive protein r =+0.08, P=0.09 r =20.06, P=0.16
Homocysteine r =+0.24, P,0.00001 r = +0.24, P,0.00001
Cysteine r =+0.21, P=0.00001 r = +0.27, P,0.00001
Taurine r =+0.10, P = 0.03 r = +0.01, P= 0.79
Glutamylcysteine r =+0.30, P,0.00001 r = +0.35, P,0.00001
Glutathione r =+0.10, P=0.03 r = +0.16, P= 0.0004
Cysteinylglycine r =+0.14, P=0.002 r = +0.12, P= 0.007
doi:10.1371/journal.pone.0054870.t002
Table 3. Forward stepwise regression of serum ADMA
concentrations.
Variables B coefficient (95% CI) P-value
Log age 0.130 (0.054 to 0.205) 0.001
Gender (0 = female,
1 =male)
20.017 (20.033 to 20.002) 0.03*
Log body mass index 0.066 (0.018 to 0.114) 0.008
eGFR 20.00047 (20.00101 to 0.00006) 0.08*
Beta blockers (0 = no,
1 = yes)
0.022 (0.002 to 0.041) 0.03*
Log homocysteine 0.035 (0.005 to 0.064) 0.02*
Glutamylcysteine 0.011 (0.004 to 0.018) 0.003
Variables entered in the model: age, gender, body mass index, current alcohol
use, hypertension, myocardial infarction, stroke, eGFR, C-reactive protein, total
cholesterol, LDL-cholesterol, antiplatelet drugs, angiotensin converting enzyme
inhibitors, statins, diuretics, beta-blockers, homocysteine, glutamylcysteine,
cysteinylglycine, cysteine, glutathione, taurine.
*not significant after adjusting level of significance (P,0.01).
doi:10.1371/journal.pone.0054870.t003
Table 4. Forward stepwise regression of serum SDMA
concentrations.
Variables B coefficient (95% CI) P-value
Log age 0.142 (0.057 to 0.227) 0.001
Log body mass index 20.070 (20.124 to 20.016) 0.012*
Diabetes 20.043 (20.069 to 20.017) 0.001
eGFR 20.00260 (20.00317 to 20.00203) ,0.00001
Cysteine 0.00034 (0.00009 to 0.00059) 0.007
Glutamylcysteine 0.015 (0.007 to 0.023) 0.00009
Variables entered in the model: age, body mass index, current alcohol use,
myocardial infarction, stroke, eGFR, C-reactive protein, total cholesterol, LDL-
cholesterol, antiplatelet drugs, angiotensin converting enzyme inhibitors,
diuretics, beta-blockers, homocysteine, glutamylcysteine, cysteinylglycine,
cysteine, glutathione.
*not significant after adjusting level of significance (P,0.01).
doi:10.1371/journal.pone.0054870.t004
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the first step of the transsulfuration pathway, and ADMA
concentrations [7,16–19]. Possible mechanisms for the increased
ADMA concentrations include the involvement of the methionine-
homocysteine pathway in the biosynthesis of ADMA and the
homocysteine-mediated inhibition of ADMA metabolism by the
enzyme DDAH [21,22]. This might explain the co-existence of
elevated homocysteine and ADMA concentrations, vascular
damage, and adverse outcomes reported in several studies
[7,37–39]. By contrast, no independent associations were observed
between homocysteine and SDMA concentrations. Significant
independent associations between homocysteine and SDMA have
been previously reported [7,19,40]. Although clinical and demo-
graphic factors were considered in these studies, a possible reason
for the different results in our study is the combined assessment of
several transsulfuration pathway thiols, some showing stronger
independent associations with SDMA.
The thiol glutamylcysteine showed the strongest independent
associations with higher ADMA and SDMA concentrations.
Glutamylcysteine, the immediate precursor of glutathione, is
synthesised by the enzyme glutamylcysteine synthetase. The
catalytic activity of glutamylcysteine synthetase depends on the
availability of cysteine and is inhibited by glutathione [41]. There
is increasing evidence that glutamylcysteine plays an important
role in modulating oxidative stress and cardiovascular risk.
Nakamura et al have recently reported a significant dose-
dependent reduction in markers of oxidative stress in human
endothelial cells exposed to glutamylcysteine [42]. Although
intracellular concentrations might differ from serum glutamylcys-
teine concentrations the effects on oxidative stress were observed
at concentrations, i.e.$50 mmol/L, significantly higher than those
reported in our study. Moreover, polymorphisms of the enzyme
glutamylcysteine synthetase are associated with reduced endothe-
lial function and increased risk of myocardial infarction [43].
There are at least two possible mechanisms by which glutamyl-
cysteine might modulate ADMA and SDMA concentrations: 1) a
direct inhibitory effect of glutamylcysteine on DDAH expression
and/or activity, with a consequent increase in ADMA concentra-
tions, similarly to that reported with homocysteine [21,22]; 2) the
role of glutamylcysteine as part of the c-glutamyl cycle. The latter
has been shown to modulate the trans-membrane transport of
several amino acids, including arginine [44]. A similar phenom-
enon might involve the methylated forms ADMA and SDMA.
Further in vitro research is necessary to corroborate these findings
and to provide mechanistic insights.
An independent and positive association, not previously
reported, was also demonstrated between the thiol cysteine and
SDMA concentrations. Whether this reflects the role of cysteine in
the c-glutamyl cycle, similarly to glutamylcysteine, and potentially
in SDMA transport requires further studies. Glutathione and
taurine have been shown to modulate DDAH activity in vitro. It
has been speculated that the effects on DDAH activity are largely
mediated by the antioxidant effects of these thiols [45–47].
However, no associations were observed between glutathione,
taurine, and methylated arginines.
The association between several clinical and demographic
characteristics, e.g. age, renal function, and body mass index, and
methylated arginine concentrations is in line with previous reports
[1,2,48]. Although the independent negative association between
body mass index and serum SDMA concentrations is apparently
counterintuitive, our results are in line with a recently published
study. Schwedhelm et al observed negative associations between
body mass index and SDMA concentrations both in univariate
(r =20.13, P,0.001) and regression analyses (B coefficient
20.0031, P,0.01) [19]. Two further studies have demonstrated
independent negative associations between SDMA and insulin
resistance, commonly associated with higher body mass index
[49,50]. Similarly, we observed a negative association between
fasting serum glucose and SDMA (Table 2). It has been speculated
that insulin resistance might selectively promote cellular uptake of
SDMA through increased expression of the y+ transporter [51].
However, further research is warranted to clarify this issue.
Although female gender was associated with higher ADMA
concentrations in our study, previous reports on the impact of
gender on ADMA have provided conflicting results. This might be
secondary to differences in study population, e.g. age, and
statistical approach [52–54]. The use of beta-blockers as a class
was associated with higher ADMA concentrations. Previous
studies have shown contrasting effects of beta-blockers on ADMA
concentrations. It is possible that the discrepancy in the results of
these reports depends, at least partly, on the use of specific beta-
blockers [55–57]. Of note, a history of diabetes was independently
associated with lower SDMA concentrations. As diabetes is
frequently associated with the presence of kidney disease, hence
a reduced SDMA clearance, this finding is also apparently
counterintuitive. However, a recent study has demonstrated that
SDMA concentrations in patients with type 2 diabetes depend on
glycaemic control. Can et al observed that patients with relatively
poor glycaemic control had lower SDMA concentrations vs.
patients with good control and healthy subjects [58]. The presence
of a negative correlation between SDMA and both HbA1c and
fructosamine suggests an interaction between protein methylation
and glucose homeostasis [58]. Moreover, as previously discussed,
there is evidence that SDMA is inversely associated with insulin
resistance [49,50]. In line with these findings our study demon-
strated negative correlations between fasting serum glucose
concentrations and SDMA concentrations (Table 2).
A limitation of our study is its cross-sectional nature, which does
not allow the assessment of cause-effect relationship between
transsulfuration thiols and methylated arginines. Moreover,
similarly to most population studies on methylated arginines, the
measurement of transsulfuration thiols, ADMA, and SDMA from
blood does not necessarily reflect intracellular concentrations of
these compounds. Another important issue is the risk of falsely
positive associations due to multiple comparisons in regression
analysis. Adjustment of the level of significance according to
established approaches, e.g. Bonferroni correction, might be too
conservative in this context [59]. Although the level of significance
was lowered to P,0.01 in regression analysis, the possibility of
data over-interpretation cannot be ruled out. On the other hand,
strengths of this study are the combined assessment of transsul-
furation thiols and the adjustment for several clinical, demograph-
ic, biochemical, and pharmacologic confounders in regression
analysis.
Conclusions
This study has shown significant associations between three
transsulfuration pathway thiols, particularly glutamylcysteine, and
methylated arginines at population level. Further in vitro studies are
necessary to clarify the mechanism responsible for these associa-
tions, e.g. direct effects on ADMA metabolism and/or interactions
between the c-glutamyl cycle and amino acid transmembrane
transport.
Supporting Information
Figure S1 Scatter plots between individual serum thiols
and ADMA concentrations.
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